ADMA Biologics (ADMA) Competitors $15.69 +0.39 (+2.55%) Closing price 04:00 PM EasternExtended Trading$15.58 -0.11 (-0.73%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADMA vs. ACAD, AKRO, ALLO, FGEN, SMMT, ASND, VTRS, RDY, QGEN, and BBIOShould you be buying ADMA Biologics stock or one of its competitors? The main competitors of ADMA Biologics include ACADIA Pharmaceuticals (ACAD), Akero Therapeutics (AKRO), Allogene Therapeutics (ALLO), FibroGen (FGEN), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. ADMA Biologics vs. Its Competitors ACADIA Pharmaceuticals Akero Therapeutics Allogene Therapeutics FibroGen Summit Therapeutics Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Qiagen BridgeBio Pharma ACADIA Pharmaceuticals (NASDAQ:ACAD) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment. Does the media favor ACAD or ADMA? In the previous week, ACADIA Pharmaceuticals had 13 more articles in the media than ADMA Biologics. MarketBeat recorded 18 mentions for ACADIA Pharmaceuticals and 5 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.12 beat ACADIA Pharmaceuticals' score of 0.96 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, ACAD or ADMA? ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioACADIA Pharmaceuticals$957.80M4.22$226.45M$1.3318.02ADMA Biologics$426.45M8.78$197.67M$0.8618.24 Do analysts prefer ACAD or ADMA? ACADIA Pharmaceuticals currently has a consensus target price of $29.65, indicating a potential upside of 23.74%. ADMA Biologics has a consensus target price of $27.67, indicating a potential upside of 76.33%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts plainly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ACADIA Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.65ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Do institutionals & insiders believe in ACAD or ADMA? 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is ACAD or ADMA more profitable? ADMA Biologics has a net margin of 44.06% compared to ACADIA Pharmaceuticals' net margin of 21.80%. ADMA Biologics' return on equity of 41.01% beat ACADIA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ACADIA Pharmaceuticals21.80% 14.69% 9.41% ADMA Biologics 44.06%41.01%28.47% Which has more volatility & risk, ACAD or ADMA? ACADIA Pharmaceuticals has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. SummaryACADIA Pharmaceuticals and ADMA Biologics tied by winning 8 of the 16 factors compared between the two stocks. Get ADMA Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADMA vs. The Competition Export to ExcelMetricADMA BiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.74B$3.08B$5.69B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio18.2421.3075.8626.51Price / Sales8.78379.80489.92165.32Price / Cash29.7644.4425.8129.89Price / Book10.609.6112.846.32Net Income$197.67M-$53.28M$3.28B$270.51M7 Day Performance-4.27%0.31%0.22%2.15%1 Month Performance-7.65%4.58%4.61%6.35%1 Year Performance-13.79%9.24%68.33%25.48% ADMA Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADMAADMA Biologics3.6549 of 5 stars$15.69+2.5%$27.67+76.3%-15.4%$3.74B$426.45M18.24530Positive NewsACADACADIA Pharmaceuticals4.3239 of 5 stars$25.39+0.5%$28.88+13.7%+51.2%$4.28B$957.80M19.09510AKROAkero Therapeutics3.8859 of 5 stars$44.57-0.3%$81.14+82.1%+56.7%$3.57BN/A-22.2930Analyst DowngradeALLOAllogene Therapeutics2.8267 of 5 stars$1.14-0.9%$8.44+640.7%-61.1%$252.94M$20K-1.03310Analyst DowngradeFGENFibroGen4.4649 of 5 stars$11.16-7.8%$43.00+285.3%+0.8%$45.09M$29.62M-29.37570News CoverageAnalyst UpgradeGap DownSMMTSummit Therapeutics3.3707 of 5 stars$19.44-25.2%$33.79+73.8%-40.7%$14.44B$700K-19.25110Positive NewsAnalyst ForecastHigh Trading VolumeASNDAscendis Pharma A/S2.9554 of 5 stars$205.22-0.3%$244.36+19.1%+63.2%$12.56B$393.54M-39.771,017Positive NewsVTRSViatris1.6033 of 5 stars$10.48-0.2%$10.40-0.8%-17.7%$12.22B$14.74B-3.6132,000RDYDr. Reddy's Laboratories2.4264 of 5 stars$14.27-0.5%$16.95+18.8%-9.0%$11.91B$334.26B21.6127,811Positive NewsQGENQiagen4.4124 of 5 stars$47.62+0.1%$49.69+4.4%+0.7%$10.58B$1.98B28.135,765Positive NewsBBIOBridgeBio Pharma4.4324 of 5 stars$54.29+1.7%$63.35+16.7%+96.6%$10.38B$221.90M-13.27400Analyst Forecast Related Companies and Tools Related Companies ACAD Alternatives AKRO Alternatives ALLO Alternatives FGEN Alternatives SMMT Alternatives ASND Alternatives VTRS Alternatives RDY Alternatives QGEN Alternatives BBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADMA) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADMA Stock Alerts